RxDoctor Payments Data

Charles Mahakian, MD

Psychiatry · Las Vegas, NVNPI 1881780724

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,305 and has fallen 74.5% since, to $332 in 2023.

$4,195in general payments, 2019–2025

Across 318 payments — averaging $13.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$787
  • AbbVie$727
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$540
  • Sunovion Pharmaceuticals Inc.$479
  • Johnson & Johnson$319
  • Alkermes, Inc.$294
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,13599%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,195 in reported general payments places this provider in the 85th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$61,874
Medicare patients
137
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$56,960
RexultiBrexpiprazole35$56,571
VraylarCariprazine Hcl15$23,138
Aripiprazole286$21,304
Asenapine Maleate52$15,958
VyvanseLisdexamfetamine Dimesylate20$7,874
Ziprasidone Hcl46$7,761
Olanzapine OdtOlanzapine45$6,905
Risperidone370$6,630
Clozapine44$6,604
Atomoxetine Hcl46$6,346
Quetiapine Fumarate302$5,676
Divalproex Sodium ErDivalproex Sodium75$5,256
Doxepin Hcl39$5,208
Lisdexamfetamine Dimesylate20$4,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$319$56,96016 claims
Otsuka America Pharmaceutical, Inc.Rexulti$787$56,57135 claims
AbbVieVraylar$727$23,13815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →